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The Epstein–Barr virus nuclear antigen-1 promotes telomere dysfunction via induction
of oxidative stress
SA Kamranvar and MG Masucci
Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden
The Epstein–Barr virus (EBV) nuclear antigen (EBNA)-1 pro-
motes the accumulation of chromosomal aberrations in malig-
nant B cells by inducing oxidative stress. Here we report that
this phenotype is associated with telomere dysfunction. Stable
or conditional expression of EBNA1 induced telomere abnorm-
alities including loss or gain of telomere signals, telomere
fusion and heterogeneous length of telomeres. This was
accompanied by the accumulation of extrachromosomal telo-
meres, telomere dysfunction-induced foci (TIFs) containing
phosphorylated histone H2AX and the DNA damage response
protein 53BP1, telomere-associated promyelocytic leukemia
nuclear bodies (APBs), telomeric-sister chromatid exchanges
and displacement of the shelterin protein TRF2. The induction
of TIFs and APBs was inhibited by treatment with scavengers of
reactive oxygen species (ROS) that also promoted the reloca-
lization of TRF2 at telomeres. These ﬁndings highlight a novel
mechanism by which EBNA1 may promote malignant transfor-
mation and tumor progression.
Leukemia (2011) 25, 1017–1025; doi:10.1038/leu.2011.35;
published online 11 March 2011
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Introduction
Genetic instability associated with telomere dysfunction is an
early event in tumorigenesis.
1,2 The telomeres consist of 3–12kb
long repeats of the hexameric nucleotide 50-TTAGGG-30 bound
to a protein complex that includes TRF1, TRF2, POT1, TIN2,
TPP1 and RAP1, collectively known as the shelterin complex.
3,4
The repeats terminate with a G-rich 100–200 nucleotide long
single-strand 30 overhang that is sequestered in a telomere loop,
5
which prevents the recognition of chromosome termini as
double-strand breaks.
6 Telomeric DNA is synthesized by
telomerase, an RNA-dependent reverse transcriptase complex
whose activity is tightly regulated by subcellular localization
and by the activity of the shelterin proteins. In particular, TRF1
and TRF2 control the replication and protection of telomeres
and function as negative regulators of telomere length,
7,8
whereas the poly-(ADP-ribose)-polymerase tankyrase promotes
telomere elongation by regulating the binding of TRF1 to
telomeric DNA.
9
The telomeres are shortened at each cell division because of
incomplete replication of the chromosome termini. When the
length falls below a critical threshold, p53 is activated and
induces a p16- and retinoblastoma protein-dependent replica-
tive senescence.
10,11 In the absence of functional checkpoints,
progressive shortening and defects of telomere capping elicit
DNA damage responses and repair of the chromosome ends by
homologous recombination or non-homologous end joining,
which promotes chromosomal aberrations and genomic
instability.
12 In most cancers, telomere length is maintained by
upregulation of telomerase activity,
13 but a telomerase-inde-
pendent mechanism, referred to as alternative lengthening of
telomeres (ALT), operates in some tumors.
14–17 One important
hallmark of ALT is the presence of heterogeneous telomeres that
range from almost undetectable to 450kb in length.
18 Another
identiﬁable marker is the presence of promyelocytic leukemia
nuclear bodies containing telomeric DNA and shelterin proteins
known as ALT-associated promyelocytic leukemia nuclear
bodies (APBs).
16 In addition to promyelocytic leukemia (PML)
and SP100, APBs also contain several DNA repair proteins,
19
suggesting that they may constitute a DNA damage response
triggered by uncapped or damaged telomeres.
20,21 The associa-
tion between ALT and dysfunctional telomeres is further
supported by the occurrence of extrachromosomal telomere
sequences, frequently t-circles, and telomeric-sister chromatid
exchanges in ALT-positive cells.
18
Epstein–Barr virus (EBV) has been implicated in the pathogen-
esis of a variety of lymphoid and epithelial cell malignancies
including post-transplant lymphomas, endemic Burkitt’s
Lymphoma, nasopharyngeal carcinoma, a subset of Hodgkin’s
disease and gastric carcinoma.
22 Infection of B lymphocytes
is accompanied by the expression of viral genes, which sustains
the establishment of EBV-carrying lymphoblastoid cell lines with
extended growth potential in vitro. Their products include six
EBV nuclear antigens (EBNA1, -2, -3A, -3B, -3C and -LP), three
latent membrane proteins (LMP1, -2A, -2B), two non-translated
RNAs (EBER1 and EBER2) and several microRNAs,
23,24 but only
EBNA1 is regularly detected in all EBV-associated malignan-
cies.
24 Although unable to trigger cell proliferation and lacking
tumorigenic potential in animal models,
25,26 EBNA1 was shown
to induce genomic instability in malignant B cells, as manifested
by the occurrence of non-clonal chromosomal aberrations,
oxidative DNA damage and activation of the DNA damage
response.
27,28
In this study, we have investigated the effect of EBV latency
proteins on the maintenance of telomere integrity in virus-
infected cells. We report that EBNA1 promotes telomere
dysfunction via induction of oxidative DNA damage.
Materials and methods
Cell lines
The cell lines used in this investigation are listed and referenced
in Supplementary Information Table S1. All cells were cultured
in RPMI1640 supplemented with 10% fetal calf serum, 2mM
Received 13 July 2010; revised 4 January 2011; accepted 28 January
2011; published online 11 March 2011
Correspondence: Professor MG Masucci, Department of Cell and
Molecular Biology, Karolinska Institutet, Box 285, Stockholm
S-171 77, Sweden.
E-mail: maria.masucci@ki.se
Leukemia (2011) 25, 1017–1025
& 2011 Macmillan Publishers Limited All rights reserved 0887-6924/11
www.nature.com/leuglutamine, 100U/ml penicillin and 0.1mg/ml streptomycin,
(Sigma-Aldrich, St Louis, MO, USA). BJAB sublines expressing
EBNA1, EBNA-3A and EBNA-3C were kept in medium
supplemented with 2mg/ml geneticin (Gibco, Darmstadt,
Germany), and sublines carrying the tet-off transactivator were
kept in medium supplemented with 0.5mg/ml hygromycin B
(Calbiochem, Darmstadt, Germany) and either 1mg/ml puro-
mycin (Calbiochem) or 2mg/ml geneticin (Sigma-Aldrich) for
BJAB-tTAE1 and BJAB-tTALMP1, respectively. Expression of the
viral proteins was repressed by culture in medium containing
2mg/ml doxycycline (Sigma-Aldrich). Endogenous reactive
oxygen species (ROS) levels were measured by DCFDA
staining,
29 and quenching was achieved by culturing the cells
in medium containing 3.5mM Ebselen (Alexis Biochemicals, San
Diego, CA, USA) for 1 week.
Immunoblotting
Cell lysates were prepared in lithium dodecyl sulfate sample
buffer, fractionated in precast 4–12% NUPAGE gels (Invitrogen,
Carlsbad, CA, USA) and transferred to polyvinylidene ﬂuoride
membranes (Millipore, Bedford, MA, USA). The blots were
probed with antibodies to EBNA1 (OT1x mouse monoclonal
antibody 1:1000, kind gift of Jaap Middeldorp, Vrije Univer-
siteit, Amsterdam, The Netherlands), EBNA-3A (rabbit serum
1:1000, ASLA, Riga, Latvia), EBNA-3C (mouse monoclonal
1:5000, kind gift of Martin Rowe, University of Birmingham,
Birmingham, UK), LMP1 (S12 hybridoma supernatant 1:10000),
TRF1, hTERT (sc.56807 1:1000, sc-7212 1:250, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), TRF2, Tankyrase, POT1,
Tin2 (IMG124A 1:1000, IMG-146 1:500, IMG-5343A 1:1000,
IMG-282 1:500 IMGENEX, San Diego, CA, USA), TPP1
(ab39042 1:500, Abcam, Cambridge, MA, USA) followed by
the appropriate HRP-conjugates secondary antibody (Zymed,
San Francisco, CA, USA), developed by enhanced chemilumi-
nescence and analyzed using the Fuji LAS 1000 system (FujiFilm
Medical Systems Inc., Stamford, CT, USA).
Quantitative Fluorescence in situ hybridization
(Q-FISH)
Exponentially growing cells were treated with 30ng/ml colce-
mide (KaryoMAX Invitrogen) for 90min to induce metaphase
arrest, washed in hypotonic buffer containing 75mM KCl
(Sigma-Aldrich), ﬁxed in methanol/acetic acid (3:1) and dropped
onto cold glass slides. Telomeres were visualized using the
Telomere PNA FISH kit, (DAKO, Glostrup, Denmark). The slides
were ﬁxed in 3.7% formaldehyde (Merck, Darmstadt, Germany)
for 10min and washed twice in Tris-buffered saline, treated with
proteinase K for 10min at room temperature and dehydrated by
consecutive 2min incubations in 70, 85 and 100% cold
ethanol. After air-drying, hybridization solution containing the
peptide nucleic acid probe was added followed by heat
denaturation for 5min at 801C and incubation for 2h at room
temperature in the dark. The slides were then overlaid with
washing solution for 5min at 651C, dehydrated and mounted
with 4’,6-diamidino-2-phenylindole-containing Vectashield
(Vector Laboratories, Inc., Burlingame, CA, USA). Digital
images were captured using a LEITZ-BMRB ﬂuorescence
microscope (Leica, Wetzlar, Germany) equipped with a CCD
camera (Hamamatsu Photonics, Japan) and analyzed using
Adobe Photoshop (Adobe Photoshop CS4; Adobe systems Inc.,
San Jose, CA, USA). Chromosomes were counted and the
ﬂuorescence intensity of each telomeric signal was scored using
the ImageJ software (http://rsb.info.nih.gov). The results are
expressed as integrated density (ID¼50pix/inch
2) of telomere
signals in 25 randomly selected metaphase plates from three
independent experiments.
Detection of TIFs and APBs by immunoﬂuorescence-FISH
(IF-FISH)
Cells (3 10
4) in 0.1ml phospahte-buffered saline were
deposited on glass slides by cytospin centrifugation, ﬁxed in
fresh 3.7% formaldehyde for 10min and permeabilized with
0.1% Triton X-100 for 5min. After blocking with 3% fetal calf
serum for 30min, the slides were incubated for 1h at room
temperature with antibodies to PML (mouse monoclonal anti-
body1:100, kind gift of Hugues de The ´, University of Paris, Paris,
France), phosphorylated histone 2AX (pH2AX) (05-636 1:100,
Upstate Biotechnology, CA, USA) or 53BP1 (612523 1:100, BD
Biosciences, NJ, USA) followed by Alexa Fluor 555-conjugated
donkey antimouse antibodies (Invitrogen) for 30min. After
washing and, ﬁxation with 2% formaldehyde for 10min
quantitative ﬂuorescent in situ hybridization (Q-FISH) was
performed as described above.
Detection of telomere sister chromatid exchanges
by chromosome orientation-FISH (CO-FISH)
The cells were grown in medium containing 10mM BrdU/BrdC
(3:1) (BrdU, Sigma-Aldrich and BrdC, MP Biomedicals, IIIkirch,
France) for 16h and chromosome slides were prepared as
described. After treatment with 0.5mg/ml RNAase A (Invitrogen)
for 10min at 371C, staining with 0.5mg/ml Hoechst 33258 in
2 SSC for 15min at room temperature and crosslinking by
exposure to 365-nm UV light (Stratalinker 1800, Agilent
Technologies, St Clara, CA, USA) for 30min, the slides were
digested with 10U/ml Exonuclease III (Fermentas, Leon-Rot,
Germany) for 10min at room temperature and sequentially
incubated with TAMRA-TelG 50-(TTAGGG)3-30 and FITC-TelC
50-[CCCTAA]3-30 probes (Cambridge Research Biomedicals,
Cleveland, UK) at room temperature for 2h.
Quantiﬁcation of telomere-associated TRF2
Cytospin slides were permeabilized with 0.1% Triton X-100
followed by ﬁxation in fresh 2% paraformaldehyde (Sigma-
Aldrich) for 20min, blocking with 2% bovine serum albumin
(BSA) for 30min and overnight incubation at 41C with the anti-
TRF2 antibody. Q-FISH was then performed as described.
Digital images were analyzed with the Volocity Software
(Improvision, University of Warwick Science Park, England).
Telomeres (red ﬂuorescence) were identiﬁed in hundred nuclei
and the average intensity of red (telomere) and green (TRF2)
ﬂuorescence within each selected area was quantiﬁed.
Statistical analysis
Statistical analysis was performed using Student’s t-test. P-values
p0.05 were considered as signiﬁcant.
Results
Telomere aberrations in EBNA1-expressing cells
Previous studies demonstrating the presence of abnormal
telomeres and chromosomal aberrations in a restricted panel
of EBV-positive and -negative Burkitt’s Lymphoma lines
suggested that EBV carriage may be associated with telomere
dysfunction.
27 To verify this observation, the analysis was
extended to a larger panel of paired cell lines including in vitro
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LeukemiaEBV-converted sublines of the EBV-negative Ramos and BJAB
and EBV genome-loss variants of the EBV-positive Burkitt’s
Lymphoma lines Akata and Oma. Representative micrographs
illustrating the type of telomere aberrations recorded in Q-FISH-
stained metaphase plates are shown in Figure 1A and
a compilation of the frequency of these aberrations in paired
EBV-positive and-negative cell lines is presented in Supplemen-
tary Information Figure S1A. Although four clearly distinguish-
able telomere signals of similar intensities were detected in the
majority of chromosomes from the EBV-negative BJAB, Ramos,
Akata ( ) and Oma cl.4 (Figure 1A, panel a, Supplementary
Figure S1A), more than 40% of the chromosomes in the EBV-
carrying cell lines showed less than four telomere signals
(Figure 1A panels b, c, d), fused telomeres (Figure 1A panels e,
f), telomeres of widely different ﬂuorescence intensity
(Figure 1A, panels b, f, g) or interstitial telomeres (Figure 1A,
panels h, i, j). Quantiﬁcation of the intensity of individual
telomere signals in three independent experiments, each
including 25 randomly selected metaphases, revealed a cell-
line speciﬁc variation in total signal that was only marginally
inﬂuenced by the presence of EBV (Figure 1B). However,
although a narrow distribution of signal intensity was regularly
observed in the EBV-negative cell lines, EBV carriage was
associated with a remarkable broadening of the signal intensity
distribution, conﬁrming the increased heterogeneity of telomere
size detected by visual inspection of the micrographs.
In order to investigate which EBV latent protein might be
responsible for this phenotype, the distribution of telomere
signal intensity was compared in the EBV-negative BJAB and in
transfected sublines stably expressing EBNA1, -3A, -3C and
LMP1. Expression of the viral proteins was in each case
conﬁrmed in western blots probed with speciﬁc antibodies
(Figure 1C and Supplementary Information Figure S1B inserts).
A signiﬁcant broadening of telomere signal distribution was
observed in the EBNA1 transfectant (Figure 1C, left panel),
whereas expression of EBNA-3A, -3C and LMP1 had no effect
(Supplementary Information Figure S1B). The effect of EBNA1
was conﬁrmed by visual scoring of chromosome-associated
telomere signals, which revealed a signiﬁcant increase in
the number of chromosomes with abnormal telomeres
Figure 1 EBNA1 expression induces telomere aberrations and telomere length heterogeneity. (A) Representative micrographs of BJAB-E1
metaphase chromosomes illustrating the telomere aberrations scored in EBV-positive and -negative cell lines: (a) chromosome with four telomere
signals of equal intensity; (b–d) chromosomes lacking one or more telomere signal; (e, f) chromosomes with fused telomeres; (g) chromosome with
telomere signals of different intensity; (h–j) chromosomes with interstitial telomeres. (B) Quantiﬁcation of telomere signal intensity in pairs of
EBV-negative and -positive cell lines. The telomeres were detected by quantitative (Q)-FISH in three independent experiments, each including 25
randomly selected metaphases and signal intensity represented as integrated pixel density (ID, 50pix/inch
2) was quantiﬁed using the ImageJ
software. (C) Intensity of telomere signals detected by Q-FISH in BJAB sublines expressing stable (BJAB-E1, left panel) or inducible EBNA1
(BJAB-tTAE1, right panel). BJAB-tTAE1 cells were kept in the presence or absence of doxycycline for 1 month before the assay. EBNA1 expression
was conﬁrmed in western blots probed with the OT1x antibody (inserts).
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ening of telomere signal intensity was observed within 4 weeks
of doxycycline withdrawal in the BJAB-tTAE1 cell line that
carries a conditional EBNA1 (Figure 1C, right panel). Thus,
EBNA1 expression is associated with several morphological
signs of telomere dysfunction including loss or gain of telomere
signals and wide heterogeneity of telomere length.
EBNA1 induces telomere dysfunction
Telomere dysfunction is caused by the impairment of control
mechanisms that maintain telomere integrity, which leads to
telomere breaks and activation of telomere-speciﬁc DNA
damage responses attempting to repair the damage.
30 Imprecise
repair results in the accumulation of extrachromosomal
telomeric DNA repeats, principally in the form of t-circles.
18
As illustrated by representative Q-FISH of metaphase plates from
BJAB-E1 cells (Figure 2a) and summarized in Figure 2b, a
signiﬁcant increase of extrachromosomal telomeric DNA was
observed in stably transfected BJAB and Ramos and was induced
upon doxycycline withdrawal in the BJAB-tTAE1 cell line,
conﬁrming that expression of EBNA1 is associated with DNA
breakage at telomeres.
DNA damage response factors such as pH2AX and 53BP1 are
recruited at dysfunctional telomeres in nuclear foci known as
telomere dysfunction-induced foci (TIFs),
12 and the activation of
DNA repair is associated with the appearance of telomere-
associated promyelocytic leukemia nuclear bodies (APBs) in
which PML colocalizes with telomeric DNA and telomere-
associated proteins.
16 IF-FISH staining for telomeres and
pH2AX, 53BP1 or PML was performed in EBNA1-positive and
-negative Ramos cells. Examination of one focal plane per
nucleus revealed a signiﬁcant increase of pH2AX, 53BP1 and
PML foci in the EBNA1-positive cells (Figure 2c, left panel) and
dual staining conﬁrmed that many of these foci colocalize with
telomeres (Figure 2c, merged). A compilation of the results
obtained in three independent experiments is shown in
Figure 2d. A comparable EBNA1-associated increase of TIFs
and APBs was observed in the BJAB-E1 and BJAB-tTAE1 cell
lines (data not shown), although the possibility of chance
colocalization could not be unequivocally excluded in these
cells because of the small size of telomeres detected by Q-FISH
in interphase nuclei.
Telomere-sister chromatid exchange is often observed in cells
with damaged or eroded telomeres.
31 Analysis of telomere-sister
chromatid exchange by chromosome orientation (CO)-FISH
±
±
-
Figure 2 EBNA1 expression induces telomere dysfunction. (a) Representative Q-FISH illustrating the occurrence of extra-chromosomal telomeric
signals (arrows) in BJAB-E1. The chromosomes were stained with 4’,6-diamidino-2-phenylindole (DAPI). (b) Mean±s.d. of extrachromosomal
telomere positive cells scored in 25 metaphase spreads of EBNA1-positive and-negative cell lines in three independent experiments.
*Pp0.01.
(c) Representative immunoﬂuorescence-FISH (IF-FISH) micrographs illustrating the presence of APBs (upper panels), 53BP1 (middle panels) and
pH2AX (lower panels) foci in Ramos and Ramos-E1. PML, 53BP1 and pH2AX immunoﬂuorescence in green and telomeres Q-FISH in red. The
nuclei were stained by DAPI (blue). (d) Compilation of the % of cell containing one or more telomeric APB, pH2AX and 53BP1 foci in EBNA1-
positive and-negative Ramos in three independent experiments in which at least 25 nuclei were scored.
*Pp0.01.
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Leukemiausing G-rich (lagging strand template, Figure 3a, left panels) and
C-rich (leading strand template, Figure 3a middle panel) probes
demonstrated a signiﬁcant ﬁvefold increase of telomere-sister
chromatid exchange in EBV-positive Ramos compared with the
EBV-negative parental and a similar increase was observed in
the Ramos-E1 transfectant, conﬁrming that EBNA1 expression is
sufﬁcient for the effect (Figures 3a and b). Collectively these
ﬁndings demonstrate that EBNA1 expression is associated with
the induction of telomere dysfunction as detected by extra-
chromosomal telomere signals and accumulation of TIFs, APBs
and telomeric-sister chromatid exchanges.
EBNA1 promotes telomere uncapping via induction of
oxidative stress
Telomere uncapping is a common cause of DNA damage at
telomeres.
32 In order to assess whether telomere deprotection
might explain the telomere dysfunction phenotype induced by
EBNA1, we ﬁrst investigated the expression of components of
the shelterin complex and other telomere-associated proteins.
To this end, western blots of cell lysates from paired EBNA1-
negative and -positive cell lines were sequentially probed with
appropriately selected cocktails of antibodies speciﬁc for the
DNA-binding subunits, TRF1, TRF2 and POT1, associated
components of the shelterin complex, TPP1 and TIN2, and the
telomere homeostasis-related proteins TANK and TERT. Repre-
sentative western blots are shown in Figure 4a. The expression
of EBNA1 was not associated with regular changes in the
intensity of the speciﬁc bands, although minor differences in the
expression levels of individual protein were occasionally
observed. Similar results were obtained in all the cell lines
examined in this study, including EBV-converted sublines of
BJAB and Ramos and EBV-positive and loss variants of Akata
and Oma Burkitt’s Lymphomas (data not shown).
Binding of TRF2 is essential for telomere protection.
7 Having
ascertained that EBNA1 does not inﬂuence the expression of
TRF2, we then asked whether the localization of TRF2 might be
affected. Telomeres and TRF2 were visualized in EBNA1-
positive and -negative cells by IF-FISH and the amount of
telomere-associated TRF2 was quantiﬁed. Representative
images illustrating the colocalization of TRF2 (green ﬂuores-
cence) and telomere signals (red ﬂuorescence) in Ramos and
Ramos-E1 are shown in Figure 4b. A striking decrease in the
intensity of TRF2 signals associated with telomere was observed
in EBNA1-positive cells in which several telomeres appeared to
lack any associated TRF2 ﬂuorescence (indicated by arrows).
Quantiﬁcation of telomere ﬂuorescence intensity in 100 nuclei
conﬁrmed that EBNA1 expression was associated with a
broadening of the telomere signal distribution (Figure 4c,
horizontal axis) and with a signiﬁcant decrease in the amount
of telomere-associated TRF2 ﬂuorescence (Figure 3c, vertical
axis and Figure 4d). Similar results were obtained on compar-
ison of the BJAB and BJAB-E1 cell lines (data not shown).
Figure 3 Expression of EBNA1 is associated with enhanced telomere-sister chromatid exchange. (a) Representative micrographs illustrating the
occurrence of telomere-sister chromatid exchange in EBV-converted and EBNA1-transfected Ramos. Chromosome orientation-FISH (CO-FISH)
was performed with the telomere strand-speciﬁc probes TelC (leading strand template, red) and TelG (lagging strand template, green), telomere-
sister chromatid exchange is visualized by colocalization of red and green signals on the same telomere (arrows). (b) Compilation of the results
obtained in two independent CO-FISH experiments. A ﬁvefold increase of telomere-sister chromatid exchange-positive chromosomes was
detected in EBV-converted and EBNA1-transfected Ramos cells.
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in B lymphocytes through transcriptional upregulation of the
NADPH oxidase NOX2 and consequent accumulation of
ROS.
28 We therefore asked whether the telomere dysfunction
phenotype could be attributed to the induction of ROS. We ﬁrst
tested whether oxidative stress induces TIFs and APBs in EBV-
negative cells. In accordance with previous reports demonstrat-
ing that mild oxidative stress induces telomere erosion,
33 short
treatment of EBV-negative Ramos with 10 or 50mM H2O2
induced levels of TIFs and APBs comparable to those observed
in the Ramos-E1 transfectant (Supplementary Information Figure
S2A). We then sought to establish a link between telomere
dysfunction and the increased endogenous levels of ROS in
EBNA1-expressing cells. To this end, Ramos-E1 cells were
cultured for 1 week in a medium containing 3.5mM of the ROS
scavenger glutathione peroxidase mimetic Ebselen before
detection of APBs by IF-FISH. As previously reported,
28 Ebselen
treatment was associated with a signiﬁcant decrease in the
levels of ROS measured by DCFDA staining (data not shown)
and with virtually complete disappearance of pH2AX foci
(Figure 5a, upper panel). This correlated with a signiﬁcant
reduction of APBs (Figure 5a lower panel and Figure 5b),
indicating that ROS-dependent DNA damage is critically
involved in the induction of telomere dysfunction in EBNA1-
expressing cells. We then asked whether the capacity of Ebselen
to inhibit the formation of APBs was also associated with
restoration of telomere protection as measured by telomeric
localization of TRF2. To this end, telomeres and TRF2 were
detected by IF-FISH in Ramos and Ramos-E1, and the intensity
of telomere colocalized TRF2 signals was quantiﬁed. As
illustrated by the representative experiments shown in
Figure 5c and summarized in Supplementary Information Figure
S2B, treatment with Ebselen resulted in reconstitution of
telomere-associated TRF2 ﬂuorescence to levels comparable to
those observed in the EBV-negative Ramos cell line. Collec-
tively, these results support the conclusion that oxidative stress
mediates the induction of telomere dysfunction through
displacement of the shelterin protein TRF2.
Discussion
EBV is a human tumor virus and a potent growth-transforming
agent for human B cells. Virus carriage is associated with
increased genomic instability in B-cell lymphomas.
27 In this
study, we have documented the occurrence of telomere
Figure 4 EBNA1 induces telomere deprotection by displacement of TRF2. (a) Representative western blot illustrating the expression of shelterin
and telomere proteins in EBNA1-positive and -negative BJAB and Ramos. Total cell lysates were fractioned by SDS-PAGE, and blots were
sequentially probed with cocktails of the indicated antibodies. (b) Decrease of telomere-associated TRF2 in EBNA1-expressing cells.
Representative micrographs illustrating the colocalization of TRF2 (green) and telomere (red) signals in Ramos and Ramos-E1. Telomeres lacking
colocalized green ﬂuorescence are indicated by arrows. (c) Quantiﬁcation of telomere and telomere localized TRF2 signals. The cells were stained
by immunoﬂuorescence-FISH (IF-FISH) and telomeres and TRF2 were identiﬁed by means of red and green ﬂuorescence in 100 nuclei. (d) The
intensity of green ﬂuorescence overlapping with each red telomere was quantiﬁed using the Volocity software. One representative experiment out
of three is shown in the ﬁgure.
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Leukemiadysfunction in EBV-infected cells and identiﬁed EBNA1 as the
viral protein causing this phenotype via induction of oxidative
stress-dependent telomere uncapping.
Numerous signs of telomere dysfunction accumulate in B-cell
lines upon stable or inducible expression of EBNA1, including a
striking heterogeneity in telomere length (Figure 1), a signiﬁcant
increase of extrachromosomal telomeric DNA, accumulation of
DNA damage response and repair proteins at telomeres
(Figure 2), and an approximately ﬁvefold increase of telomere-
sister chromatid exchange (Figure 3). Failure of the machinery
that controls telomere capping is a major trigger of telomere
dysfunction in proliferating cells.
30 Thus, loss of TRF2 in cells
expressing dominant-negative mutants or speciﬁc small hairpin
RNAs, and deletion of POT1 were shown to induce activation of
the DNA damage response, aberrant chromosome recombina-
tion and genomic instability.
7,34 The effect of EBNA1 on the
accumulation of TIFs containing DNA-damage response pro-
teins (Figure 2) was paralleled by the displacement of TRF2 from
telomeres (Figure 4). It is noteworthy that the levels of TRF2
detected by western blot in total cell lysates were not
signiﬁcantly changed, which may reﬂect the selective increase
of an extra-telomeric TRF2 pool.
35 TRF2 was shown to
cooperatively bind with EBNA1 to the origin of viral replication
OriP
36 and may be recruited to other EBNA1-binding sites on
cellular DNA. However, we have failed to demonstrate any
interaction of TRF2 with EBNA1 by co-immunoprecipitation and
could not convincingly demonstrate localization of EBNA1 at
telomeres.
The uncertain fate of the displaced TRF2 notwithstanding, the
accumulation of telomeric foci of DNA-damage response
proteins strongly supports the involvement of telomere depro-
tection in the telomere dysfunction phenotype induced by
EBNA1. Our previous ﬁnding that EBNA1 induces oxidative
DNA damage and genomic instability by transcriptional
upregulation of the catalytic subunit of the NADPH oxidase
NOX2
28 provided an important insight on the possible
mechanism of this effect. Oxidative stress causes telomere
dysfunction,
37 which is at least partly due to a diminished
binding of TRF1 and TRF2 to oxidized telomeric DNA.
33 We
have found that, although mild oxidative stress induced levels of
TIFs and APBs comparable to those induced by EBNA1
expression in EBV-negative cells (Supplementary Information
Figure S2), the formation of TIFs and APBs was inhibited in
EBNA1-positive cells when the endogenous levels of ROS were
decreased by treatment with Ebselen (Figure 5). Most impor-
tantly, this was associated with relocalization of TRF2 at
telomeres, establishing a direct correlation between the
oxidative stress induced by EBNA1 and telomere uncapping.
The telomere abnormalities associated with EBNA1 expres-
sion are characteristic features of ALT, a mechanism that
maintains telomere homeostasis in a subset of malignant cells
with poor or absent telomerase activity.
17 Previous reports
demonstrating that EBV conversion does not alter the activity of
telomerase in B-lymphoma lines
38 speak against a direct effect
of EBNA1 on telomerase, which is also supported by our failure
to observe changes in the expression of TERT and other
telomere-associated proteins in cells expressing stable or
inducible EBNA1 (Figure 4). It is noteworthy that persistent
telomerase activity may not preclude the activation of recombi-
nation-dependent mechanisms for telomere elongation as ALT
was shown to remain active upon reconstitution of telomerase
activity in ALT-positive cell lines.
39,40 The possibility that EBV
may activate telomerase-independent mechanisms for main-
tenance of telomere homeostasis is line with the observations
Figure 5 EBNA1 promotes telomere dysfunction via induction of ROS. Ramos and Ramos-E1 were cultured in the presence of the ROS scavenger
Ebselen for 1 week before the assays. (a) Representative micrographs illustrating the effect of Ebselen on the presence of pH2AX foci (upper panel)
and APBs detected by PML (green) and telomere (red) colocalization (lower panel, arrows). (b) Quantiﬁcation of APBs in control and Ebselen
treated Ramos-E1. Mean±s.d. of three experiments.
*Pp0.01 (c) Ebselen treatment promotes the relocalization of TRF2 at telomere.
Quantiﬁcation of telomere and telomere localized TRF2 signals was performed as described in the legend of Figure 4c. One representative
experiment out of three is shown in the ﬁgure.
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Leukemiathat the average length of telomeres remains relatively constant
during the early phases of EBV-induced growth transforma-
tion,
41,42 whereas a robust upregulation of telomerase activity is
only detected after several weeks or months in culture.
41
Furthermore, some EBV immortalized lymphoblastoid cell lines
overcome a growth crisis after approximately 150 passages
in vitro in the absence of detectable telomerase activity.
43
Conceivably, if EBV activates ALT, this could rescue the infected
cells from replicative senescence during the early phase of
B-cell immortalization. The inherently imprecise recombination
mechanisms that underlie ALT may also give rise to telomeres
too short for efﬁcient capping and therefore exposed to
inappropriate repair and chromosomal aberration. This scenario
is in line with the high frequency of non-clonal chromosomal
aberrations in EBNA1-expressing B-lymphoma lines,
27 and is
also supported by the recent ﬁndings of Lacoste et al.
42 who,
although monitoring the evolution of lymphoblastoid cell lines
from the time of EBV infection, observed high karyotypic
instability during the ﬁrst 10–25 weeks in culture followed by
stabilization approximately at the time when a signiﬁcant
upregulation of telomerase activity would be expected.
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